MedTrace Logo

Monovalent Recombinant COVID19 Vaccine

NCT04453852 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-03-02

No results posted yet for this study

Summary

This is a study to test a new vaccine (Covax-19) against COVID-19. COVID-19 is a potentially deadly disease that is caused by a new strain of coronavirus called SARS-CoV-2. To date, SARS-CoV-2 has infected over 4 million people worldwide resulted in the deaths of over three hundred thousand people.

Conditions

  • Coronavirus Infection
  • COVID

Interventions

BIOLOGICAL

COVID19 vaccine

COVID19 recombinant spike protein with Advax-SM adjuvant

BIOLOGICAL

Saline

Saline control

Sponsors & Collaborators

  • Central Adelaide Local Health Network Incorporated

    collaborator OTHER_GOV

  • Vaxine Pty Ltd

    lead INDUSTRY

Principal Investigators

  • David Gordon, MBBS, Ph.D · CALHN

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-30
Primary Completion
2021-02-01
Completion
2021-04-14

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04453852 on ClinicalTrials.gov